跳至主要内容
临床试验/NCT07102056
NCT07102056尚未招募不适用

Prospective Study of 18F-AlF-NOTA-Octreotide PET-CT or PET-MR in Diagnosis, Treatment and Prognosis for Neuroendocrine Neoplasms

First Affiliated Hospital of Zhejiang University0 个研究点目标入组 152 人开始时间: 2026年1月1日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
152
主要终点
Diagnostic efficacy

研究概览

简要总结

The study aims to elucidate how 18F-Octreotide PET/CT or PET-MR can assist in accurate localization, treatment planning, prognostic predictions, and the selection of PRRT efficacy in neuroendocrine tumors. It also highlights important applications in lesion segmentation measurement, tumor grading, prognostic survival prediction, and genotype identification.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
20 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical diagnosed of neuroendocrine neoplasms.
  • Suspected of neuroendocrine neoplasms.

排除标准

  • Inability to undergo biopsy/surgical treatment.
  • Concurrent active malignancy.
  • Severe uncontrolled comorbidities/active infections.
  • Inability to provide informed consent.

结局指标

主要结局

Diagnostic efficacy

时间窗: through study completion, an average of 1.5 year

Sensitivity, specificity, positive and negative predictive value of 18F-OC PET/CT and PET/MR Imaging in neuroendocrine neoplasms

次要结局

未报告次要终点

研究者

发起方
First Affiliated Hospital of Zhejiang University
申办方类型
Other
责任方
Sponsor

相似试验